Company Information

  

Address: 9704 MEDICAL CENTER DRIVE  
City: Rockville 
State: MD 
Zip Code: 20850 
Telephone: 301-251-5172 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Except as otherwise indicated herein or as the context otherwise requires, references in this annual report on Form 10-K to "MacroGenics," the "company," "we," "us" and "our" refer to MacroGenics, Inc. and its consolidated subsidiaries. MacroGenics, the MacroGenics logo, DART, TRIDENT and the phrase "Breakthrough Biologics, Life-Changing Medicines" are our trademarks or registered trademarks. The other trademarks, trade names and service marks appearing in this report are the property of their respective owners. Overview We are a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer as well as various autoimmune disorders and infectious diseases. We currently have a pipeline of product candidates in human clinical testing that have been created primarily using our proprietary technology platforms.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-4.18NAN/E
03/2017-1.89NAN/E
12/2016-1.69NAN/E
09/2016-1.57NAN/E
06/2016-1.10NAN/E
03/2016-2.93NAN/E
12/2015-0.63NAN/E
09/2015-0.44NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.10Total Liab/Total Assets0.14
Net Inc/Total Assets-0.19Total Liab/Inv Cap0.15
Net Inc/Inv Cap-0.21Total Liab/Comm Equity0.08
Pretax Inc/Net Sales-0.64Interest Coverage RatioNA
Net Inc/Net Sales-0.64Curr Debt/EquityNA
Cash Flow/Net Sales-0.48LTD/EquityNA
SG&A/NetSales0.32Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover46.08Quick Ratio10.40
Inventory TurnoverNACurrent Ratio10.40
Inventory Day SalesNANet Rec/Curr Assets0.01
Net Sales/Work Cap0.36Inv/Curr AssetsNA
Net Sales/PP&E5.12  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 1.67 2.06 5.11 3.26
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 8.38 7.46 9.24 7.22
Operating Income -41.18 -38.21 -35.24 -34.27
Interest Exp NA NA NA NA
Pretax Income -40.66 -37.66 -34.78 -33.85
Other Income 0.53 0.55 0.46 0.42
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -40.66 -37.66 -34.78 -33.85

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 243.66 243.10 277.00 311.12
Receivables - Total 1.99 2.09 2.76 3.01
Inventories - Total NA NA NA NA
Total Current Assets 250.11 251.01 283.95 316.29
Net Property, Plant & Equipment 23.18 17.38 17.96 18.47
Total Assets 274.85 274.72 311.26 339.86
Liabilities        
Accounts Payable 24.41 19.47 20.13 16.74
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 29.89 26.55 27.30 22.05
Long-Term Debt NA NA NA NA
Total Liabilities 43.50 40.08 42.51 39.76
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.37 0.35 0.35 0.35
Retained Earnings -371.02 -330.37 -292.71 -257.93
Treasury Stock NA NA NA NA
Total Stockholders' Equity 231.35 234.64 268.75 300.10
Total Liabilities and Stockholders' Equity 274.85 274.72 311.26 339.86

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -30.76 -35.33 -28.33 49.79
Net Cash Provided by Investing Activities 73.13 -8.36 2.03 -3.16
Net Cash Provided by Financing Activities 33.73 0.11 0.49 1.01

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201263.838.36--
12/201358.04-0.26-0.04
12/201447.80-38.31-1.40
12/2015100.85-20.14-0.63
12/201691.88-58.53-1.69
Growth Rates9.54----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1712431,13884.62




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.